3
H index
1
i10 index
30
Citations
Martina Garau : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 1 Articles 21 Papers 1 Books RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
12 years (2006 - 2018). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Martina Garau. | Is cited by:
| Cites to:
|
Main data
Where Martina Garau has published?
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Consulting Reports / Office of Health Economics | 10 |
| Research Papers / Office of Health Economics | 7 |
| Briefings / Office of Health Economics | 3 |
Recent works citing Martina Garau (2018 and 2017)
| Year | Title of citing document |
|---|---|
| 2018 | Funding breakthrough therapies: A systematic review and recommendation. (2018). Hanna, E ; Auquier, P ; Badora, K ; Dabbous, O ; Borissov, B ; Dussart, C ; Toumi, M. In: Health Policy. RePEc:eee:hepoli:v:122:y:2018:i:3:p:217-229. Full description at Econpapers || Download paper |
| 2019 | Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?. (2019). Trapero-Bertran, M ; Aranda-Reneo, I ; Ramos-Goi, J M ; Lopez-Bastida, J ; Martin, Rodriguez B ; Kanavos, P. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:2:p:152-158. Full description at Econpapers || Download paper |
| 2019 | Competition between on-patent medicines in Europe. (2019). Wilsdon, Tim ; Roediger, Alexander ; Azais, Boris ; Pendleton, Kathy ; Haderi, Artes. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:7:p:652-660. Full description at Econpapers || Download paper |
| 2018 | The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century. (2018). Bagley, Nicholas ; Stern, Ariel Dora ; Garthwaite, Craig ; Chandra, Amitabh. In: NBER Chapters. RePEc:nbr:nberch:14097. Full description at Econpapers || Download paper |
| 2018 | Establishing a Reasonable Price for an Orphan Drug. (2018). Berdud, Mikel ; Towse, A ; Drummon, M F. In: Research Papers. RePEc:ohe:respap:002036. Full description at Econpapers || Download paper |
| 2017 | Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval. (2017). Chambers, James D ; Neumann, Peter J ; Kamal-Bahl, Sachin J ; Subedi, Prasun ; Salem, Mark ; Wilkinson, Colby L ; Thorat, Teja . In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0291-9. Full description at Econpapers || Download paper |
| 2017 | Amplifying Each Patient’s Voice: A Systematic Review of Multi-criteria Decision Analyses Involving Patients. (2017). Marsh, Kevin ; Zaiser, Erica ; Hamed, Alaa ; Caro, Jaime J. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0299-1. Full description at Econpapers || Download paper |
| 2018 | Does MCDA Trump CEA?. (2018). Culyer, Anthony ; Puig-Junoy, Jaume ; Campillo-Artero, Carlos. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:16:y:2018:i:2:d:10.1007_s40258-018-0373-y. Full description at Econpapers || Download paper |
| 2018 | New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. (2018). Varnava, Alice ; Routledge, Philip A ; Hughes, Dyfrig A ; Samuels, Karen ; Bracchi, Robert. In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:5:d:10.1007_s40273-018-0632-7. Full description at Econpapers || Download paper |
Works by Martina Garau:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2009 | Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries In: Briefings. [Full Text][Citation analysis] | paper | 5 |
| 2007 | Estimating Pharmaceutical Companies Value to the Nation: Case Study of the British Pharma Group In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2011 | Exploring the Interdependency between Public and Charitable Medical Research In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2010 | Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2009 | Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2006 | Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2014 | Obstructive Sleep Apnoea: Health Economics Report In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2016 | Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Policy Options for Formulary Development in Middle-income Countries In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2018 | Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2007 | European Medicines Pricing and Reimbursement: Now and the Future In: Monographs. [Full Text][Citation analysis] | book | 0 |
| 2011 | Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Papers. [Full Text][Citation analysis] | paper | 1 |
| 2013 | Exploring the link between health and wealth in decision making In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2013 | Multi-Criteria Decision Analysis to Value Orphan Medicines In: Research Papers. [Full Text][Citation analysis] | paper | 10 |
| 2012 | Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Papers. [Full Text][Citation analysis] | paper | 3 |
| 2010 | Using QALYs in Cancer: Review of the Methodological Limitations In: Research Papers. [Full Text][Citation analysis] | paper | 8 |
| 2014 | Exploring the Interdependencies of Research Funders in the UK In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
| 2016 | Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open. [Full Text][Citation analysis] This paper has another version. Agregated cites: 0 | article | |
| 2018 | R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 2nd 2019. Contact: CitEc Team